Challenges in the management of the transgender patient with sickle cell disease

Am J Hematol. 2018 Nov;93(11):E360-E362. doi: 10.1002/ajh.25242. Epub 2018 Oct 12.

Authors

Jocelyn Ronda¹, Anne Nord², Renata Arrington-Sanders¹, Rakhi Naik³, Clifford M Takemoto⁴, Jacquelyn Baskin², Sophie Lanzkron³, Lydia H Pecker⁴

Affiliations

¹ Johns Hopkins Medicine, Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, Baltimore, Maryland.
² Children's Hospital Los Angeles, Department of Pediatrics, Division of Pediatric Hematology, Los Angeles, California.
³ Johns Hopkins Medicine, Department of Medicine, Division of Hematology, Baltimore, Maryland.
⁴ Johns Hopkins Medicine, Department of Pediatrics, Division of Pediatric Hematology, Baltimore, Maryland.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell / drug therapy*
Anemia, Sickle Cell / psychology
Disease Management
Female
Gonadal Steroid Hormones / adverse effects
Gonadal Steroid Hormones / pharmacology
Gonadal Steroid Hormones / therapeutic use*
Hormones / adverse effects
Hormones / pharmacology
Hormones / therapeutic use
Humans
Male
Middle Aged
Pulmonary Embolism / chemically induced
Transgender Persons*
Treatment Outcome
Young Adult

Substances

Gonadal Steroid Hormones
Hormones

Grants and funding